The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: A no-net-flux microdialysis study

Neuroscience

Volumn 159, Issue 4, 2009, Pages 1292-1299

  Ferris, M J ^a   Frederick Duus, D ^b   Fadel, J ^b   Mactutus, C F ^a   Booze, R M ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cocaine; dopamine; dopamine transporter; HIV; microdialysis; Tat

Indexed keywords

COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; HUMAN IMMUNODEFICIENCY VIRUS 1 ASSOCIATED PROTEIN; RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NERVE DEGENERATION; NERVE ENDING; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MALE; MICRODIALYSIS; NEURONS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REGRESSION ANALYSIS; SYNAPSES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TIME FACTORS;

EID: 63349109514     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.01.024     Document Type: Article

References (49)

1. Aksenova M.V., Silvers J.M., Aksenov M.Y., Nath A., Ray P.D., Mactutus C.F., and Booze R.M. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: Changes in dopamine transporter binding and immunoreactivity. Neurosci Lett 395 (2006) 235-239
2. Aksenov M.Y., Hasselrot U., Wu G., Nath A., Anderson C., Mactutus C.F., and Booze R.M. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, ox-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res 987 (2003) 1-9
3. Aksenov M.Y., Hasselrot U., Bansal A.K., Guanghan W., Nath A., Anderson C., Mactutus C.F., and Booze R.M. Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci Lett 305 (2001) 5-8
4. An S.F., Groves M., Gray F., and Scaravilli F. Early entry and widespread cellular involvement of HIV-1 DNA in brain of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol 58 (1999) 1156-1162
5. Bellizzi M.J., Lu S.M., and Gelbard H.A. Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurological disease. J Neuroimmune Pharmacol 1 (2006) 20-31
6. Berger J.R., and Nath A. HIV dementia and the basal ganglia. Intervirology 40 (1997) 122-131
7. Bradley J.V. Complete counterbalancing of immediate sequential effects in a Latin square design. J Am Stat Assoc 53 (1958) 525-528
8. Cadet J.L., Krasnova I.N., Jayanthi S., and Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotoxicol Res 11 (2007) 183-202
9. Chang L., Wang G.J., Volkow N.D., Ernst T., Telang F., Logan J., and Fowler J.S. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage 42 (2008) 869-878
10. Chen L., Ding Y., Cagniard B., Van Laar A.D., Mortimer A., Chi W., Hastings T.G., Kang U.J., and Zhuang X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28 (2008) 425-433
11. Edelstein H., and Knight R.T. Severe parkinsonism in two AIDS patients taking prochlorperazine. Lancet 2 (1987) 341-342
12. Factor S.A., Podskalny G.D., and Barron K.D. Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: A clinico-pathological case report. J Neurol Sci 127 (1994) 114-120
13. Ferris M.J., Frederick-Duus D., Fadel J., Mactutus C.F., and Booze R.M. In vivo microdialysis in awake, freely-moving rats, demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 63 (2009) 181-185
14. Ferris M.J., Mactutus C.F., and Booze R.M. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: Current status of dopamine system vulnerability in neuroAIDS. Neurosci Biobehav Rev 32 (2008) 883-909
15. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM (2007) Altered striatal dopamine transmission in rats exposed to the HIV-1 Tat protein and cocaine. Abstract presented at the Society of Neuroimmune Pharmacology meeting, Salt Lake City, UT.
16. Fitting S., Booze R.M., Hasselrot U., and Mactutus C.F. Differential long-term neurotoxicity of HIV-1 proteins in the hippocampal formation: A design-based stereological study. Hippocampus 18 (2008) 135-147
17. Floyd R.A., Hensley K., Jaffery F., Maidt L., Robinson K., Pye Q., and Stewart C. Increased oxidative stress brought on by pro-inflammatory cytokines in neurodegenerative processes and the protective role of nitrone-based free radical traps. Life Sci 65 (1999) 1983-1899
18. Gelman B.B., Spencer J.A., Holzer III C.E., and Soukup V.M. Abnormal striatal dopaminergic synapses in national NeuroAIDS Tissue Consortium Subjects with HIV encephalitis. J Neuroimmune Pharmacol 1 (2006) 410-420
19. Hinkin C.H., Barclay T.R., Castellon S.A., Levine A.J., Durvasula R.S., Marion S.D., Myers H.F., and Longshore D. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 11 (2007) 185-194
20. Hollander H., Golden J., Mendelson T., and Cortland D. Extrapyramidal symptoms in AIDS patients given low-dose metoclopropamide or chlorpromazine. Lancet 2 (1985) 186
21. Hriso E., Kuhn T., Masdeu J., and Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 148 (1991) 1558-1561
22. Imam S.Z., Newport G.D., Itzhak Y., Cadet J.L., Islam F., Slikker Jr. W., and Ali S.F. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem 76 (2001) 745-749
23. Kalivas P.W., and Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 13 (1993) 266-275
24. Koutsilieri E., Sopper S., Scheller C., ter Meulen V., and Riederer P. Parkinsonism in HIV dementia. J Neural Transm 109 (2002) 767-775
25. Malone S.B., and Osborne J.J. Improving treatment adherence in drug abusers who are HIV-positive. Lippincotts Case Manag 5 (2000) 236-245
26. Mollace V., Nottet H.S., Clayette P., Turco M.C., Muscoli C., Salvemini D., and Perno C.F. Oxidative stress and neuroAIDS: triggers, modulators, and novel antioxidants. Trends Neurosci 24 (2001) 411-416
27. Mollace V., and Nistico G. Release of nitric oxide from astroglial cells: A key mechanism in neuroimmune disorders. Adv Neuroimmunol 5 (1995) 421-430
28. Mattson M.P., Haughey N.J., and Nath A. Cell death in HIV dementia. Cell Death Differ 1 Suppl (2005) 893-904
29. Nath A., Maragos W.F., Avison M.J., Schmitt F.A., and Berger J.R. Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol 7 (2001) 66-71
30. NIDA. Drug abuse and AIDS. NIDA Infofacts: November 2004 (2004). http://www.drugabuse.gov
31. Parsons L.H., Smith A.D., and Justice Jr. J.B. The in vivo microdialysis recovery of dopamine is altered independently of basal level by 6-hydroxydopamine lesions to the nucleus accumbens. J Neurosci Methods 40 (1991) 139-147
32. Paul R.H., Brickman A.M., Navia B., Hinkin C., Malloy P.F., Jefferson A.L., Cohen R.A., Tate D.F., and Flanigan T.P. Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. J Neuropsychiatr Clin Neurosci 17 (2005) 167-171
33. Paul R.H., Cohen R.A., Navia B., and Tashima K. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev 26 (2002) 353-359
34. Peters J.L., and Michael A.C. Modeling voltammetry and microdialysis of striatal extracellular dopamine: the impact of dopamine uptake on extraction and recovery ratios. J Neurochem 70 (1998) 594-603
35. Pierce R.C., and Kumaresan V. The mesolimbic dopamine system the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci Biobehav Rev 30 (2006) 215-238
36. Quinton M.S., and Yamamoto B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 12 (2006) E337-E347
37. Robinson T.E., Castañeda E., and Whishaw I.Q. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. Can J Psychol 44 (1990) 253-275
38. Smith A.D., and Justice Jr. J.B. The effect of inhibition of synthesis, release, metabolism and uptake on the microdialysis extraction fraction of dopamine. J Neurosci Methods 54 (1994) 75-82
39. Sporer B., Linke R., Seelos K., Paul R., Klopstock T., and Pfister H.W. HIV-induced chorea: evidence for basal ganglia dysregulation by SPECT. J Neurol 252 (2005) 356-358
40. Tang A., Bungay P.M., and Gonzales R.A. Characterization of probe and tissue factors that influence interpretation of quantitative microdialysis experiments for dopamine. J Neurosci Methods 126 (2003) 1-11
41. Thompson A.C., Zapata A., Justice Jr. J.B., Vaughan R.A., Sharpe L.G., and Shippenberg T.S. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20 (2000) 9333-9340
42. Turchan J., Anderson C., Hauser K.F., Sun Q., Zhang J., Liu Y., Wise P.M., Kruman I., Maragos W., Mattson M.P., Booze R.M., and Nath A. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2 (2001) 3
43. Turchan J., Pocernich C.B., Gairola C., Chauhan A., Schifitto G., Butterfield D.A., Buch S., Narayan O., Sinai A., Geiger J., Berger J.R., Elford H., and Nath A. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 60 (2003) 307-314
44. UNAIDS/WHO. AIDS epidemic update: December (2007). http://www.unaids.org
45. Venton B.J., Seipel A.T., Phillips P.E., Wetsel W.C., Gitler D., Greengard P., Augustine G.J., and Wightman R.M. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci 26 (2006) 3206-3209
46. 1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59 (2006) 51-60
47. Wang G.J., Chang L., Volkow N.D., Telang F., Logan J., Ernst T., and Fowler J.S. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127 (2004) 2452-2458
48. Westerink B.H. Brain microdialysis and its application for the study of animal behaviour. Behav Brain Res 70 (1995) 103-124
49. Zahniser N.R., and Sorkin A. Rapid regulation of the dopamine transporter: role in stimulant addiction?. Neuropharmacology 47 Suppl 1 (2004) 80-91